NASDAQ:VSTM Verastem (VSTM) Stock Price, News & Analysis $6.86 -0.01 (-0.15%) Closing price 11/19/2026 04:00 PM EasternExtended Trading$6.98 +0.11 (+1.68%) As of 11/19/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Verastem Stock (NASDAQ:VSTM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Verastem alerts:Sign Up Key Stats Today's Range$6.81▼$7.2050-Day Range$6.86▼$10.1052-Week Range$3.43▼$10.82Volume3.72 million shsAverage Volume3.23 million shsMarket Capitalization$864.43 millionP/E RatioN/ADividend YieldN/APrice Target$16.83Consensus RatingModerate Buy Company Overview Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer. Its research has centered on signaling pathways involved in tumor growth, including the RAS/MAPK pathway. The company’s product, AVMAPKI FAKZYNJA CO-PACK, combines avutometinib and defactinib. The U.S. Food and Drug Administration approved the combination for certain adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. Verastem is based in Needham, Massachusetts, and also develops investigational cancer therapies, including potential uses of avutometinib in combination with other medicines.AI Generated. May Contain Errors. Read More Verastem Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreVSTM MarketRank™: 2.155837004405 of 5 starsVerastem scored higher than 43% of companies evaluated by MarketBeat, and ranked 593rd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingVerastem has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 11 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialVerastem has a consensus price target of $16.83, representing about 145.4% upside from its current price of $6.86.Amount of Analyst CoverageVerastem has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Verastem's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Verastem are expected to decrease in the coming year, from ($1.88) to ($2.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verastem is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verastem is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerastem has a P/B Ratio of 85.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.15% of the float of Verastem has been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 5.17.Change versus previous monthShort interest in Verastem has recently increased by 14.34%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerastem does not currently pay a dividend.Dividend GrowthVerastem does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.27 News SentimentVerastem has a news sentiment score of -0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Verastem this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for VSTM on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $386,390.00 in company stock.Percentage Held by Insiders1.94% of the stock of Verastem is held by insiders.Percentage Held by Institutions88.37% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verastem's insider trading history. Receive VSTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VSTM Stock News HeadlinesVerastem Appoints Michael Bailey as Incoming Chief Executive OfficerNovember 19 at 5:30 PM | tipranks.comVerastem Oncology Presents Updated Clinical Data from Phase 1/2 Target-D-101 Study of Vs-7375 in KRAS G12d-Mutated Metastatic Non-Small Cell Lung CancerNovember 18 at 1:32 PM | marketscreener.comMUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it. | Profits Run (Ad)Verastem Oncology Announces Late-Breaking Oral Presentation of VS-7375 Lung Cancer Data at IASLC/ASCO 2026 North America Conference on Lung CancerNovember 18 at 1:32 PM | finance.yahoo.comVerastem (VSTM) Stock May Be Undervalued Despite VS7375 ProgressNovember 14, 2026 | finance.yahoo.comVerastem, Inc. (NASDAQ:VSTM) Stock Has Consensus Target Price of $16.83November 10, 2026 | americanbankingnews.comVerastem (NASDAQ:VSTM) Stock Gets Price Target Cut from Royal Bank Of CanadaNovember 9, 2026 | americanbankingnews.comVerastem (NASDAQ:VSTM) CEO Sells $12,470.40 in StockNovember 6, 2026 | insidertrades.comSee More Headlines VSTM Stock Analysis - Frequently Asked Questions How have VSTM shares performed this year? Verastem's stock was trading at $7.72 at the beginning of the year. Since then, VSTM stock has decreased by 11.1% and is now trading at $6.86. How were Verastem's earnings last quarter? Verastem, Inc. (NASDAQ:VSTM) posted its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by $0.27. The biopharmaceutical company earned $24.01 million during the quarter, compared to the consensus estimate of $26.57 million. Verastem had a negative net margin of 178.38% and a negative trailing twelve-month return on equity of 359.49%. Read the conference call transcript. When did Verastem's stock split? Verastem shares reverse split before market open on Thursday, June 1st 2023.The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Verastem IPO? Verastem (VSTM) raised $45 million in an initial public offering (IPO) on Friday, January 27th 2012. The company issued 4,500,000 shares at a price of $9.00-$11.00 per share. Who are Verastem's major shareholders? Verastem's top institutional investors include State Street Corp (4.44%), Nantahala Capital Management LLC (1.97%), Goldman Sachs Group Inc. (1.15%) and AIGH Capital Management LLC (1.24%). Insiders that own company stock include Dan Paterson, Daniel Calkins, Brian M Stuglik, Robert E Gagnon, Michael Kauffman and Paul A Bunn. View institutional ownership trends. How do I buy shares of Verastem? Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Verastem own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verastem investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Novavax (NVAX), Advanced Micro Devices (AMD), Plug Power (PLUG) and Tesla (TSLA). Company Calendar Last Earnings11/05/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 VSTM's financial health is in the Green zone, according to TradeSmith. VSTM has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VSTM CIK1526119 Webwww.verastem.com Phone(781) 292-4200FaxN/AEmployees102Year Founded2010Price Target and Rating Average Price Target for Verastem$16.83 High Price Target$24.00 Low Price Target$12.00 Potential Upside/Downside+145.4%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($2.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$209.47 million Net Margins-178.38% Pretax Margin-177.56% Return on Equity-359.49% Return on Assets-78.60% Debt Debt-to-Equity Ratio11.19 Current Ratio1.93 Quick Ratio1.91 Sales & Book Value Annual Sales$30.91 million Price / Sales27.97 Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / Book85.75Miscellaneous Outstanding Shares126,010,000Free Float123,570,000Market Cap$864.43 million OptionableOptionable Beta0.45 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:VSTM) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.